DrugPatentWatch Database Preview
Details for Patent: 8,835,501
Which drugs does patent 8,835,501 protect, and when does it expire?
This patent has thirty-six patent family members in twenty-six countries.
Summary for Patent: 8,835,501
Title: | Pharmaceutical formulations of HDAC inhibitors |
Abstract: | This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc. |
Inventor(s): | Bastin; Richard J. (Waterford, IE), Hughes; Nicholas J. (Swindon, GB) |
Assignee: | TopoTarget UK Limited (Abingdon, Oxfordshire, GB) |
Application Number: | 11/913,191 |
Patent Claim Types: see list of patent claims | Composition; Compound; Formulation; Dosage form; Device; |
Drugs Protected by US Patent 8,835,501
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Spectrum Pharms | BELEODAQ | belinostat | POWDER;IV (INFUSION) | 206256-001 | Jul 3, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Foreign Priority and PCT Information for Patent: 8,835,501
PCT Information | |||
PCT Filed | May 11, 2006 | PCT Application Number: | PCT/GB2006/001737 |
PCT Publication Date: | November 16, 2006 | PCT Publication Number: | WO2006/120456 |
Non-Orange Book US Patents Family Members for Patent 8,835,501
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
9,856,211 | Pharmaceutical formulations of HDAC inhibitors | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 8,835,501
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Canada | 2606598 | ➤ Sign Up | |||
China | 101189003 | ➤ Sign Up | |||
China | 102579417 | ➤ Sign Up | |||
Cyprus | 1112498 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |